Synagis 100 mg/1 ml solution for injection clinical trials

A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

This study is testing a new medicine, Clesrovimab (also called MK-1654), to help protect babies and young children from a serious breathing illness called RSV. Researchers want to see how well it works and if it's safe compared to a current treatment.